Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1969 1
1987 1
1989 1
1993 1
2000 1
2001 1
2008 3
2009 3
2010 8
2011 6
2012 6
2013 2
2014 2
2015 2
2017 2
2018 5
2019 3
2020 4
2021 3
2022 2
2023 4
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

48 results

Results by year

Filters applied: . Clear all
Page 1
The Streptococcus agalactiae complement interfering protein combines multiple complement-inhibitory mechanisms by interacting with both C4 and C3 ligands.
Giussani S, Pietrocola G, Donnarumma D, Norais N, Speziale P, Fabbrini M, Margarit I. Giussani S, et al. FASEB J. 2019 Mar;33(3):4448-4457. doi: 10.1096/fj.201801991R. Epub 2018 Dec 19. FASEB J. 2019. PMID: 30566365 Free PMC article.
., Pietrocola, G., Donnarumma, D., Norais, N., Speziale, P., Fabbrini, M., Margarit, I. The Streptococcus agalactiae complement interfering protein combines multiple complement-inhibitory mechanisms by interacting with both C4 and C3 ligands....
., Pietrocola, G., Donnarumma, D., Norais, N., Speziale, P., Fabbrini, M., Margarit, I. The Streptococcus agalactiae complemen …
Cytosolic immunization allows the expression of preATF-saporin chimeric toxin in eukaryotic cells.
Fabbrini MS, Carpani D, Soria MR, Ceriotti A. Fabbrini MS, et al. FASEB J. 2000 Feb;14(2):391-8. doi: 10.1096/fasebj.14.2.391. FASEB J. 2000. PMID: 10657995
Such a strategy should be generally useful for the production of toxic molecules of therapeutic value whose folding and maturation require transit through the eukaryotic secretory pathway. Fabbrini, M. S., Carpani, D., Soria, M. R., Ceriotti, A. Cytosolic imm …
Such a strategy should be generally useful for the production of toxic molecules of therapeutic value whose folding and maturation require t …
The stereoselective targeting of a specific enzyme-substrate complex is the molecular mechanism for the synergic inhibition of HIV-1 reverse transcriptase by (R)-(-)-PPO464: a novel generation of nonnucleoside inhibitors.
Maga G, Ramunno A, Nacci V, Locatelli GA, Spadari S, Fiorini I, Baldanti F, Paolucci S, Zavattoni M, Bergamini A, Galletti B, Muck S, Hubscher U, Giorgi G, Guiso G, Caccia S, Campiani G. Maga G, et al. J Biol Chem. 2001 Nov 30;276(48):44653-62. doi: 10.1074/jbc.M106702200. Epub 2001 Sep 25. J Biol Chem. 2001. PMID: 11572864 Free article.
The human immunodeficiency virus type 1 (HIV-1) nonnucleoside reverse transcriptase (RT) inhibitor pyrrolopyridooxazepinone (PPO) derivative, (+/-)-PPO294, was shown to be active toward wild type and mutated HIV-1 RT and to act synergistically in combination with 3'-azido-3'-deox …
The human immunodeficiency virus type 1 (HIV-1) nonnucleoside reverse transcriptase (RT) inhibitor pyrrolopyridooxazepinone (PPO) derivative …
Risk of acute arterial and venous thromboembolic events in eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome).
Bettiol A, Sinico RA, Schiavon F, Monti S, Bozzolo EP, Franceschini F, Govoni M, Lunardi C, Guida G, Lopalco G, Paolazzi G, Vacca A, Gregorini G, Leccese P, Piga M, Conti F, Fraticelli P, Quartuccio L, Alberici F, Salvarani C, Bettio S, Negrini S, Selmi C, Sciascia S, Moroni G, Colla L, Manno C, Urban ML, Vannacci A, Pozzi MR, Fabbrini P, Polti S, Felicetti M, Marchi MR, Padoan R, Delvino P, Caporali R, Montecucco C, Dagna L, Cariddi A, Toniati P, Tamanini S, Furini F, Bortoluzzi A, Tinazzi E, Delfino L, Badiu I, Rolla G, Venerito V, Iannone F, Berti A, Bortolotti R, Racanelli V, Jeannin G, Padula A, Cauli A, Priori R, Gabrielli A, Bond M, Tedesco M, Pazzola G, Tomietto P, Pellecchio M, Marvisi C, Maritati F, Palmisano A, Dejaco C, Willeit J, Kiechl S, Olivotto I, Willeit P, Prisco D, Vaglio A, Emmi G; Italian EGPA Consortium. Bettiol A, et al. Eur Respir J. 2021 May 6;57(5):2004158. doi: 10.1183/13993003.04158-2020. Print 2021 May. Eur Respir J. 2021. PMID: 33833031 Free article. No abstract available.
Risk factors of Parkinson disease: Simultaneous assessment, interactions, and etiologic subtypes.
Belvisi D, Pellicciari R, Fabbrini A, Costanzo M, Pietracupa S, De Lucia M, Modugno N, Magrinelli F, Dallocchio C, Ercoli T, Terravecchia C, Nicoletti A, Solla P, Fabbrini G, Tinazzi M, Berardelli A, Defazio G. Belvisi D, et al. Neurology. 2020 Nov 3;95(18):e2500-e2508. doi: 10.1212/WNL.0000000000010813. Epub 2020 Sep 17. Neurology. 2020. PMID: 32943485 Free PMC article.
Proof of concept for a single-dose Group B Streptococcus vaccine based on capsular polysaccharide conjugated to Qβ virus-like particles.
Carboni F, Cozzi R, Romagnoli G, Tuscano G, Balocchi C, Buffi G, Bodini M, Brettoni C, Giusti F, Marchi S, Brogioni G, Brogioni B, Cinelli P, Cappelli L, Nocciolini C, Senesi S, Facciotti C, Frigimelica E, Fabbrini M, Stranges D, Savino S, Maione D, Adamo R, Wizel B, Margarit I, Romano MR. Carboni F, et al. NPJ Vaccines. 2023 Oct 6;8(1):152. doi: 10.1038/s41541-023-00744-5. NPJ Vaccines. 2023. PMID: 37803013 Free PMC article.
48 results